VKTX ~+25–32% — VK2735 monthly maint holds ~85% of Week-21 loss (12wk)
Posted: Tue Sep 22, 2026 6:28 pm
Viking (VKTX) ripped ~+24–32% on the session after a maintenance-phase topline for monthly VK2735 (injectable dual GLP-1/GIP): after 12 weeks off the induction dose, patients kept roughly ~85% of the Week-21 weight loss (end-of-week figure cited ~90% in wraps). That’s a Viking-specific read — LLY/NVO only soft vs the name, not a class dump. Phase 3 VANQUISH already enrolled; oral Ph3 still planned for Q4 per company messaging.
Scalper read: obesity names trade maintenance durability and oral optionality as much as induction % loss. Mark whether the bid holds into the after-hours books and if any follow-on commentary walks the “monthly maint” framing. Don’t treat a one-day VKTX squeeze as a LLY/NVO short thesis — tape said Viking-specific.
Sources (paraphrase): Viking Therapeutics topline / company release; TS2 desk wrap https://ts2.tech/en/viking-therapeutics ... ight-loss/
Holding the VKTX spike into Wed open, or fading once the maint % is digested?
Scalper read: obesity names trade maintenance durability and oral optionality as much as induction % loss. Mark whether the bid holds into the after-hours books and if any follow-on commentary walks the “monthly maint” framing. Don’t treat a one-day VKTX squeeze as a LLY/NVO short thesis — tape said Viking-specific.
Sources (paraphrase): Viking Therapeutics topline / company release; TS2 desk wrap https://ts2.tech/en/viking-therapeutics ... ight-loss/
Holding the VKTX spike into Wed open, or fading once the maint % is digested?